| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e43b4ca6b41ce9f54c9a895d474c81a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_936c907490ca37031de54b58b3097829
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9391053c1426cfcfc18776f5ee4e65f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a4b08ed26627be2c269a58fbdfc9e3f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02834888def9f5a7ef6ad2a3f72f8d62 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04 |
| filingDate |
2002-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a57146599d57f26bdc022994218bada5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f137bb0a42e2643db66825b392fc3ad4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e809c4364794d093dc50f52b8253b93
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f557e6682cef5b58f30c8876f98ef6e6 |
| publicationDate |
2003-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-03007964-A1 |
| titleOfInvention |
Remedial or preventive agent for cardiopathy or aneurysm containing chymase inhibitory compound |
| abstract |
A remedial or preventive agent for cardiopathy or aneurysm which contains as the active ingredient either a compound having the partial skeletal structure represented by the general formula (I) and having chymase inhibitory activity or a pharmacologically acceptable salt of the compound. The drug is characterized by being capable of orally administered. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8049006-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007139230-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2463268-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7888348-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8924578-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8507714-B2 |
| priorityDate |
2001-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |